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ABSTRACT 
 
The 5 year outcomes of patients receiving haemodialysis versus peritoneal 
dialysis at Groote Schuur Hospital, Cape Town, South Africa. 
 
Background: Despite the rising global prevalence of chronic kidney disease, dialysis remains 
restricted in South Africa and acceptance onto many renal replacement programs is limited 
to those suitable for transplantation.  Few studies exist comparing survival outcomes of 
peritoneal dialysis [PD] and haemodialysis [HD] patients from developing countries. In 
addition, data of those switching to HD are conflicting.  
 
Methods: This retrospective cohort study compares survival outcomes of patients receiving 
HD or PD at Groote Schuur Hospital, South Africa, from 2010- 2015.  
 
Results: 174 patients were assigned to HD and 189 to PD, of which 42 switched to HD. The 
majority (68.31%) of patients were under 45 years. More black Africans received HD. The most 
common causes of death were infection (26%) and fluid overload (19%). Having removed 
those PD patients for whom modality switch was denied due to contraindications to 
transplantation, survival probability at 1-, 2- and 5- years for HD versus PD was 98.68% (CI: 
94.84-99.67), 96.95 (CI: 91.98-98.86) and 83.52% (CI: 71.75-90.70) versus 96.73% (95% CI: 
92.32- 98.63), 89.95 (95% CI: 83.17- 94.1) and 76.69 (95% CI: 60.97- 86.73) respectively. (p= 
0.145) The survival probability of those patients who switched from PD to HD, for the same 
intervals was 100%, 97.37% (95% CI: 82.75-99.63) and 97.37 % (95% CI: 82.75-99.63). 
(p=0.001) 
 
Conclusion: In this setting, PD is not inferior to HD and those patients switching from PD to 
HD have the best survival outcomes. Therefore, the current local PD first policy is justified, 
although interventions should be aimed at improving outcomes. 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW  
INTRODUCTION 
BACKGROUND    
 
The estimated prevalence of chronic kidney disease [CKD] worldwide is escalating and is 
currently 8-16%. (1) The rising global trends of diabetes and hypertension have contributed 
to this rise.  In Sub-Saharan Africa [SSA] infectious diseases, especially HIV and tuberculosis, 
further contribute to the burden of CKD. (2) World-wide, between two and seven million 
people with CKD die each year due to the inability to access renal replacement therapy [RRT] 
and in SSA only 16% of those patients requiring dialysis actually receive maintenance therapy. 
(3) 
 
The use of PD has significantly expanded throughout the developing world in recent times as 
it is a cost effective method of RRT. Groote Schuur pioneered PD in SSA in the early 1980’s 
having initiated an HD programme a decade earlier. (4) In 2012, South Africa was reported to 
provide care for the most PD patients in Africa. (5) Currently the Western Cape has the highest 
prevalence of patients accessing renal replacement therapy in South Africa with 285 patients 
per million population. (6) 
 
RATIONING CHRONIC DIALYSIS  
 
RRT within the public sector in South Africa [SA] is restricted due to inadequate resources. (7) 
The Western Cape guidelines for rationing chronic dialysis adopted by Groote Schuur Hospital 
highlight that patients accepted for RRT should be suitable for transplantation and that the 
ethical principal of utilitarianism should guide the allocation of dialysis in our resource limited 
setting. (8) This is to ensure a turnover of patients requiring chronic dialysis. PD is initiated as 
the first modality unless there is a contraindication such as inappropriate home circumstances 
or a medical contraindication. This decision overrides patient choice. PD is continued until it 
fails and patients are then transferred to HD while awaiting kidney transplantation. A PD first 
policy is not exclusive to South Africa and exists in other areas of the world, notably Hong 
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Kong and Thailand. However, the majority studies on mortality differences have been 
conducted in North America and Europe. 
 
In order to be accepted for RRT, potential candidates are presented by the attending clinician 
to a committee of nephrologists with input from social workers, dieticians and nurses. A 
detailed psychosocial review is employed in the decision making process and factors such as 
insight, employment, schooling, living conditions, dependents and support are taken into 
account.  Previous compliance issues and drug use are highlighted in the assessment. Access 
to running household water and number of household occupants is important for PD.  
Transplanted patients who experience graft- failure and patients requiring modality switch 
are reconsidered for RRT in the same way as new patients.  An appeal procedure exists and 
an independent committee can assess the case if required. 
 
An ethically endorsed prioritization policy exists with three categories. Category 1 patients 
must be given RRT as they have the potential to gain maximum benefit with the lowest chance 
of treatment failure. Resources will always be allocated to these patients. Category 2 patients 
will be given RRT only if resources permit. Priority is given to those waiting the longest and 
those who have the best chance of successful transplantation. Both Category 1 and 2 patients 
must be suitable for transplantation. Category 3 patients are offered optimal medical 
treatment and are not offered RRT.  
 
An audit performed at Groote Schuur from 2008- 2012 showed that only 46% of patients 
presented for RRT were accepted. Younger, employed individuals and those with a superior 
psychosocial assessment are more likely to be accepted; however gender, marital status and 
area of residence were not seen to be predictors of acceptance. In univariate analysis, more 
black Africans were accepted than non-blacks, however, in multivariate analysis, race was not 
a predictor for acceptance. Diabetics and those with co-morbid diseases were less likely to be 
accepted. The result of this process is that more patients under 50 years of age are accepted 
onto the program. Black African patients are more likely to be initiated on HD as they tend to 
be living in overcrowded areas with limited access to amenities making PD more hazardous. 
(9) 
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LITERATURE REVIEW 
 
Many large studies comparing mortality outcomes for PD and HD patients have been 
performed in developed countries, where access to RRT is possible for most. This has been 
done in an effort to provide high quality evidence to guide the decision between dialysis 
modalities. In a resources limited setting, such as South Africa, this choice is superseded by 
restricted access and availability. In addition, other key factors such as the effect on quality 
of life and the cost, both to the patient and to the health care system, need to be considered 
when choosing or allocating modalities.  
 
METHODS OF LITERATURE REVIEW 
 
An extensive search of existing literature for applicable articles and papers was undertaken. 
Google Scholar, PubMed and Medline via EbscoHost were accessed via the University of Cape 
Town’s list of selected electronic resources for authorised users, allowing for full articles to 
be viewed. Key words and phrases used in these searches, either alone or in combination, 
included “h(a)emodialysis”, “peritoneal”, “dialysis”, “modality”, “comparison of”, 
“outcomes”, “mortality”, “survival”, “Africa”, “low income countries”, “South Africa” as well 
as specific search for “benefits of (peritoneal dialysis)”, “cost of dialysis”, “quality of life”.  
Searches for publications from well- known registries such the Unites States Renal Data 
System and the Australia and New Zealand Dialysis and Transplant Registry were specifically 
included. Related articles suggested by the databases were also viewed. Contemporary 
publications in peer reviewed journals with higher impact factors were favoured in the 
discussion with inclusion of smaller studies only when comparison was made or when 
literature in the area was scanty.  
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BENEFITS OF PD 
 
There are a number of proven benefits for PD which include reduced infectious complications, 
specifically septicaemia and pneumonia, avoidance of vascular access, preservation of 
residual renal function and superior patient flexibility for employment and schooling. (10–14) 
Preservation of residual renal function confers an improved survival outcome in both PD and 
HD. (14–16) However, PD has been shown to protect residual function for a greater length of 
time when compared to HD and can preserve it for up to 3 years. (17–19) In 2001, the CANUSA 
dataset was reanalysed and showed that in patients receiving PD, even a small amount of 
additional residual urine volume (250ml) was associated with 36% decreased in relative risk 
of death (RR, 0.64; 95% CI, 0.51 - 0.80). (20)  
 
QUALITY OF LIFE 
 
Previous international studies have indicated that PD patients may have a better quality of 
life than those receiving HD although the effects on mental health are similar. (21,22) Patients 
receiving chronic dialysis at Groote Schuur Hospital have been reported to have a poor health-
related quality of life, largely related to identifiable medical issues such as anaemia and 
hyperparathyroidism. However, no significant difference between the HD and PD patients 
was noted overall. (23) More recently, a different tertiary level hospital within Cape Town 
corroborated this with similar results. (24) 
 
COST  
 
A systematic review of articles reporting the cost of dialysis across low and middle-income 
countries, reported a higher cost on average for PD versus HD, although the number of studies 
were limited and standard methodology was not used. This cost difference exists despite the 
fact that substantially more infrastructure and staffing are required for HD. The cost of dialysis 
fluids and tubing were seen as the major cause for the high overall cost of PD. Countries that 
manufacture PD equipment locally or access equipment through low import duties, show that 
PD is on average significantly less expensive than HD. (25) In SA, local manufacturers produce 
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PD fluids and accessories, which are cheaper than imported products. However, in the rest of 
SSA this is not the case. 
 
Calculating the true cost between modalities is difficult due the variable timing of dialysis 
initiation and transplantation, as well as the hidden costs including staff to patient ratio of 
care, transportation and loss of productivity which may contribute to a higher overall cost for 
HD. (27) 
 
MORTALITY DIFFERENCES  
 
The issue of mortality differences between patients receiving PD versus HD is widely debated 
with several studies from across the world publishing conflicting conclusions. In 2003, in an 
effort to provide high quality evidence for outcomes in dialysis patients, an attempt at a 
randomised trial failed after doctor and patient preference was shown to significantly 
influence modality choice with only 5% of patients agreeing to modality randomisation. (26)  
 
Despite this unsuccessful attempt, a Chinese based randomized trial is currently underway 
(trial registration NCT01413074 at clinicaltrials.gov). However, until publication of this work, 
observational studies remain the source of data in the comparison of mortality in HD and PD 
patients, which will be discussed here. 
 
The survival of patients receiving both modalities has improved over the past two decades, 
although more significantly in patients receiving PD. (12) Improvements in PD survival are 
likely due to better prescription management, reduced infectious complications, widespread 
quality improvement programs and greater attention to maintaining normal fluid volume 
status. (27) This needs to be kept in mind when examining previous studies comparing 
outcomes between HD and PD patients.   
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ANALYSIS OF THE DATA 
 
In analysing the studies described below, it is important to study confounding factors and 
selection bias. All are observational studies and rely on the accuracy of data collected and 
under-reporting of co-morbidities and biochemical results, especially in earlier studies, needs 
to be considered.  
 
These studies typically use a multivariate analysis or, more recently, a propensity matching 
scoring approach to estimate mortality differences. This is because non-random assignment 
to treatment modality is being compared and these methods reduce potential bias. However, 
neither method is superior to the other as highlighted by Liem et al. (28) Some measurable 
propensity factors that were not taken into account by some authors include the use of home 
HD, body size, dialysis adequacy and volume status amongst others, which have been shown 
to influence survival. In addition to this, some propensity factors are more difficult to 
measure, for example, the degree of cardiac stunning that may occur with rapid ultrafiltration 
in HD, which may be associated with additional mortality on its own.  
 
DATA FROM DEVELOPED COUNTRIES 
NORTH AMERICA 
 
Interest in the differences between dialysis modalities was sparked by a report in 1995 by 
Bloembergen et al., when analysis of the United States Renal Data System (USRDS) showed a 
19% increase in overall mortality associated with PD when compared to HD. (29) Contrary to 
this, in 1997 Fenton et al. reported a 27% lower risk of death in Canadian patients. (30) It was 
later proposed that careful interpretation of the data was required and more sophisticated 
statistical methods were needed to provide meaningful clinical results. The use of prevalent 
rather that incident dialysis patients was also brought into question. Therefore numerous 
large registry reviews were subsequently published. 
 
The first large United States (U.S.) registry based study of incident dialysis patients was 
performed by Collins et al. (31) This study reported that PD outcomes were at least equivalent 
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to and, in subgroups, actually better than that seen in HD patients. However, it was noted 
that older, female, diabetic patients had poorer outcomes on PD. This study illustrated the 
issues with previous prevalence based studies but was limited by a lack of information on 
biochemical values and co-morbidities captured in the registry and therefore adjustments for 
these factors were not made.  
 
Subsequent U.S. studies by Ganesh et al. (32) and Stack et al. (33), showed that PD patients 
within the U.S healthcare system were younger and had fewer co-morbidities than those on 
HD and therefore it was critical that adjustment be made for these variables. By adjusting for 
these variables, both studies concluded that there was a significantly lower relative risk of 
death in PD versus HD.  
 
Vonesh et al. identified an important problem with the studies by Ganesh et al. and Stack et 
al. termed the effect modification due to age, where an element of confounding may exist 
between age and presence of co-morbidity. In an attempt to adjust for this, they then 
examined almost 400 000 patients initiating dialysis between 1995 and 2000 and used age as 
an effect modifier. They concluded that mortality differences varied widely according to the 
cause of ESRF, age, and presence of comorbidity at baseline. (34) This paper illustrated that 
mortality among PD patients had declined over time but that the same was not true for HD 
patients. In fact, in young patients who were not diabetic, a significantly higher mortality was 
observed in HD than in PD, which was concerning to many.  
 
Later, The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study, a smaller multi-
centre prospective study conducted within the U.S., showed similar outcomes in PD and HD 
patients but after the first year, HD was found to be superior. (35) It is important to note that 
this study came under criticism for having collected data after the start of dialysis and 
elements of bias in recruitment and data analysis. The lower patient numbers gave sub-group 
analysis lower statistical power. A similar Canadian prospective study (36) showed no 
significant difference between PD and HD but no sub-group analysis was performed due to 
the small numbers included in the study, an inherent problem with many prospective studies 
due to logistical reasons.  
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Mehrotra et al. examined survival outcomes in three different cohorts initiating dialysis 
between 1996- 2004 with 5 year follow-up and concluded that, although HD was favourable 
in the earlier cohorts, outcomes were equivalent for the most contemporary cohort. (37) In a 
subsequent U.S. cohort study, a review of propensity score matched pairs of patients started 
on HD and PD was conducted. The overall intention-to-treat analysis revealed survival 
favouring PD but the 4-year survival of both cohorts were comparable. (38) Subgroup analysis 
also showed that HD was superior in patients with co-morbidities such as cardiovascular 
disease and diabetes.  
 
A similar Canadian study compared patients initiating HD and PD between 1991 and 2004 
with follow up until 2007. (39) This study concluded that overall survival for the study period 
favoured PD initially but after 36 months HD showed a superior survival benefit. However, for 
the most contemporary cohort, survival favoured PD for the first 24 months and thereafter 
outcomes were similar.  This study also highlighted that female PD patients who were older 
than 65 years with diabetes, had a significantly higher mortality rate.  Mehrotra et al. 
published a similar pattern of survival outcomes for older patients and patients with diabetes 
in the U.S. (37) 
 
In 2014, Kumar et al., again in the U. S., reported outcomes that favoured PD for up to 2-3 
years. (40) No difference was seen between the cohorts thereafter. This paper has noted 
limitations as it was confined to a local area and local single health care system, all patients 
who required central venous catheters when initiating dialysis were excluded from analysis 
and under 10% of patients received PD. (41) 
 
Using data from the latest USRDS 2016 data report, PD has shown a favourable 1-, 3-, 5- and 
10- survival probability when adjusted for age, race and cause of ESRF. Overall mortality rates 
were 169 versus 157 patients per 1,000 for HD and PD respectively. Both HD and PD have 
showed a decline in mortality rates over time, although more significantly within the PD 
cohort. (42) 
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EUROPE, AUSTRALASIA AND ASIA 
Three large European registry publications exist. The Danish Terminal Uremia Registry Report 
(43), studied patients during the 1990’s and showed that for the first 2 years PD patients had 
a superior outcome but did not show the same survival advantage for older diabetic patients 
with HD, as reported in previous U.S. studies. This study made a concerted effort to adjust for 
baseline co-morbidity differences.  However, a subsequent Dutch prospective study, The 
Netherlands Cooperative Study on the Adequacy of Dialysis, followed up incident dialysis 
patients from 1997 to 2002 and noted that, although there was no difference in outcome 
between HD and PD initially, after 2 years HD was more favourable. Later, a 10-year Finnish 
registry study, notably for its adjustment for a large number of variables, concluded that there 
was no difference between PD and HD outcomes. (44) 
 
In Asia, a Taiwanese study of over 48 000 patients between 1995 and 2002 showed similar 5- 
and 10- year survival with a higher risk of death in all diabetic patients and in patients older 
than 55 years of age. (45) In Singapore, a cohort study demonstrated that HD was superior to 
PD overall but in sub-group analysis, no difference in outcome was seen in younger patients 
without co-morbidities. (46) Notable was that 70% of the patients in this study were diabetic.  
 
A review of the Australian and New Zealand Dialysis and Transplant Registry of patients 
initiated on dialysis between 1991 and 2005 showed that treatment with PD may provide an 
initial benefit but not after 12 months, when it became associated with a higher mortality 
overall. (47) However, careful inspection of the sub-group analysis showed how PD survival 
has consistently improved with time and, in the most recent cohort, outcomes between 
modalities were similar.  
 
DATA FROM DEVELOPING COUNTRIES 
 
There are few studies comparing survival outcomes of PD and HD patients from developing 
countries, however HD is still favoured in many emerging countries. (48) It is clear that further 
studies are required in low and middle income countries where barriers to PD remain 
significant. (49) 
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In 2008, the Dialysis Outcomes in Colombia report concluded that there was a non-statistically 
significant increase in adjusted mortality in patients receiving HD compared to those receiving 
PD.  (50) Colombia and South Africa are reported to have similar socioeconomic data in terms 
of Gross Domestic Product and Human Development Indexes, which includes composite 
measures of life expectancy, level of education and level of income.   
 
A Romanian registry showed that survival outcomes over three years were similar for HD and 
PD but there may be an initial benefit with PD. (51) A large Korean study using propensity 
matching showed that overall, PD was associated with a higher mortality. The poor outcomes 
in these PD patients may be related to the high prevalence of diabetes within this cohort. Sub-
group analysis again showed a high mortality seen in PD patients who were older than 55 and 
had co-morbidities. (52) Other smaller studies exist, but their cohort sizes were either too 
small to make meaningful conclusions or were conducted at a single centre making selection 
bias a notable factor. (53–55) 
 
Data from SA is limited with a recent study showing a significantly worse survival for PD 
patients. (56) This study was performed at Polokwane Kidney and Dialysis Centre and included 
340 patients, more than 90% of whom were black Africans and most were living in rural areas. 
The patient’s average travelling distance was more that 100km for both the PD and HD cohort. 
The authors concluded that limited access to health care facilities contributed largely to these 
results, highlighting the need for dialysis centres in rural South Africa. The results of this study 
have generated interest in the outcomes of patients at Groote Schuur Hospital.  
 
SWITCHING MODALITY 
 
Data on the survival of PD patients who require transfer to HD are conflicting. PD patients 
usually switch to HD when there is technique failure. This creates difficulty in comparing 
survival outcomes. In addition, PD patients are more likely to receive kidney transplantation, 
especially within the first two years. (57) In our PD-first program, the decision to switch 
modality is reviewed by a selection committee. Occasionally, a decision is made not to allow 
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for modality switch as the patient is no longer a suitable transplant candidate and therefore 
no longer fulfils the criteria for the program. 
 
Van Biesen et al. in 2000 described the concept of the “integrative care approach” where 
patients are initiated on PD and later switched to HD as indicated. This study was associated 
with improved survival outcomes compared to those patients who remained on PD, as well 
as those who were initiated and remained on HD. The results were attributed, at least in part, 
to better preservation of residual kidney function with PD. (58)  
 
In 2009, a prospective multicentre study from the United States found that although the 
frequency of switching from PD to HD was high, mortality outcomes were similar between 
those patients remaining on PD and those switching to HD. (14) Contrasting this study, Szeto 
et al. from Hong Kong  found that after 5 years almost two thirds of those patients transferring 
from PD to HD died, a mortality twice as high as that for those who were initiated and 
remained on HD. Most of the deaths occurred in the first 6 months after transfer and may be 
due to more temporary vascular catheters used in the switching group. Because “PD-first” is 
the national policy in Hong Kong, transfer to HD may also be delayed. (59) 
 
Some patients require a period of HD before being initiated on PD. Nessim et al. reviewed the 
outcomes of these patients found a higher rate of technique failure and death, especially 
within the first year compared to those initiated on PD first. (60) These outcomes have 
recently been supported by Lan et al. who also concluded that these patients were less likely 
to receive transplantation. (61) This may be due to the fact that patients who are initiated on 
PD first, without exposure to HD, may have fewer co-morbidities but other factors such as the 
loss of residual renal function, use of temporary catheters and subclinical cardiac ischaemia 
that can occur in HD may play a role.  
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CONCLUSION 
 
The complex decision of which modality to initiate a patient on needs to take into account 
the limited resources available in SA as well as the effect on quality of life with each modality. 
Further study is required to examine the true cost differences between each modality and the 
reasons for the relatively high cost of PD previously reported in developing countries. 
Although quality of life may be similar for both modalities, the ability for patients to remain 
gainfully employed or able to continue care for dependents while on dialysis should be 
promoted in our setting. Thus PD is favourable in this respect.  
 
Large, contemporary observational studies comparing overall survival have not shown a 
significant mortality difference between patients receiving HD and PD. Unfortunately, limited 
data exists from developing countries. However, PD does appear to confer a survival 
advantage, especially within the first 2 years, when initiated as the first modality. This may be 
due to temporary vascular access catheter use in HD patients but, as with all observational 
studies, selection bias may also confound these results. The use of PD in older patients and 
those with significant co-morbidities, such as cardiovascular disease and diabetes, is 
associated with poorer outcomes. The appropriate switching of a patient’s dialysis modality 
should be seen as part of an integrated care plan which has been previously shown to improve 
survival.  
 
INDICATIONS FOR THIS STUDY    
 
There are very limited published data available comparing the outcomes of adult patients 
with ESRF receiving either HD or PD in Africa, although a recent study from Limpopo Province, 
SA, concluded that there is an increased relative risk of death in patients receiving PD 
compared to HD. The decision to provide a PD first program at Groote Schuur is driven by the 
evidence that PD confers an initial survival advantage but the decision respects 
socioeconomic and infrastructural reasons too.  
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Therefore, it is necessary to examine the survival of patients receiving HD and PD as well as 
those patients switching from PD to HD at Groote Schuur Hospital to add to the scanty data 
within Africa and developing nations. The results of this study can also be used to evaluate 
the PD-first approach used at Groote Schuur Hospital and to assess the current selection 
criteria. Major causes of death can be identified so that targeted interventions are 
implemented.   
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INTRODUCTION 
 
 
The estimated prevalence of chronic kidney disease [CKD] worldwide is escalating and is 
currently 8-16%. (1) The rising global trends of diabetes and hypertension have contributed 
to this rise.  In Sub-Saharan Africa [SSA] infectious diseases, especially HIV and tuberculosis, 
further contribute to the burden of CKD. (2) World-wide, between two and seven million 
people with CKD die each year due to inability to access renal replacement therapy [RRT] and 
in SSA only 16% of those patients requiring dialysis actually received maintenance therapy. (3) 
 
RRT within the public sector in South Africa [SA] is restricted due to inadequate resources. (7) 
Suitability for kidney transplantation is the overriding criterion for acceptance onto the 
majority of public sector dialysis programs.  This is to ensure a turnover of patients requiring 
chronic dialysis. Haemodialysis [HD] positions are limited and consequently Groote Schuur 
Hospital provides a peritoneal dialysis [PD]-first program. PD is initiated as first modality 
unless there is a contraindication such as inappropriate home circumstances or a medical 
reason for exclusion. PD is continued until it fails and patients are then transferred to HD 
while awaiting kidney transplantation.  
 
Many developed countries report cost estimates that are similar for PD and HD or favour PD. 
(62,63) In 2010, Abu-Aisha et al reported an estimated annual cost for HD at Int$ 7,369.73 
and Int$ 12,633.83 for PD. (5) Calculating the true cost difference between modalities is 
difficult due to hidden costs including staff to patient ratio of care, transportation and loss of 
productivity which contribute to a higher overall cost for HD. In SA, local manufacturers 
produce PD fluids and accessories, which are cheaper than imported products. However, in 
the rest of SSA this is not the case.  
 
The proven benefits for PD include preservation of residual renal function, protection of 
vascular access sites and superior patient flexibility for employment and schooling. (10–13) 
Preservation of residual renal function confers an improved survival outcome in both PD and 
HD.(14–16) However, PD has been shown to protect residual function longer than HD and can 
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preserve it for up to 3 years. (17–19) In 2001, the CANUSA dataset was reanalysed and showed 
that in patients receiving PD, even a small amount of additional residual urine volume (250ml) 
was associated with 36% decreased in relative risk (RR) of death (RR, 0.64; 95% CI, 0.51 - 0.80). 
(20) In addition, previous studies have indicated that PD patients may have a better quality of 
life than those receiving HD. (21) 
 
The survival of patients receiving both modalities has improved over the past two decades, 
although more significantly in patients receiving PD. (12) Improvements in PD survival are 
likely due to better prescription management, reduced infectious complications, widespread 
quality improvement programs and greater attention to maintaining normal fluid volume 
status. (27) Numerous studies and large registries, including the Australia and New Zealand 
Dialysis and Transplant registry and United States Renal Data System, have demonstrated an 
initial survival benefit when PD is initiated as the first modality. (39,47,64)  
 
There are few studies comparing survival outcomes of PD and HD patients from developing 
countries, however HD is still favoured in many emerging countries. (48) Of these studies, the 
2008 Dialysis Outcomes in Colombia report concluded that there was a non-statistically 
significant increase in adjusted mortality in patients receiving HD compared to PD. (50) A 
Romanian registry showed that survival outcomes over three years were similar for HD and 
PD but there may be an initial benefit with PD. (51) Data from SA is limited with a recent study 
showing a worse survival for PD patients.(56) Further studies are required in low and middle 
income countries where barriers to PD remain significant. (49) 
 
Data on the survival of PD patients who require transfer to HD are conflicting. PD patients 
usually switch to HD when there is technique failure. This creates difficulty in comparing 
survival outcomes. In addition, PD patients are more likely to receive kidney transplantation, 
especially within the first two years. (64) In 2009, a prospective multicentre study from the 
United States found that although the frequency of switching from PD to HD was high, there 
was no difference between the mortality outcomes between those patients remaining on PD 
and those switching to HD. (14)   
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Van Biesen et al. in 2000 described the concept of the “integrative care approach” where 
patients are initiated on PD and later switched to HD as indicated. This study was associated 
with improved survival outcomes compared to those patients who remained on PD. This 
benefit was also superior to the survival of those who were initiated and remained on 
HD. The results were attributed, at least in part, to better preservation of residual kidney 
function with PD. (58) 
  
Contrasting this study, Szeto et al. from Hong Kong  found that after 5 years almost two thirds 
of those patients transferring from PD to HD died, a mortality twice as high as that for those 
who were initiated and remained on HD. Most of the deaths occurred in the first 6 months 
after transfer and may be attributable to more temporary vascular catheters used in the 
switching group. Because “PD-first” is the national policy in Hong Kong, transfer to HD may 
be delayed. (59) 
 
In our PD-first program, the decision to switch modality is reviewed by a selection 
committee. Occasionally, a decision is made not to allow for modality switch as the patient is 
no longer a suitable transplant candidate and therefore no longer fulfils the criteria for the 
program. 
 
SA provides care for the most PD patients in Africa and the most HD patients in SSA. (5,65) 
The Western Cape Province, where Groote Schuur Hospital is situated, has the highest 
prevalence of patients accessing RRT in SA [312 per million population]. (66) There are very 
limited published data available comparing the outcomes of adult patients with end stage 
renal failure (ESRF) receiving either HD or PD in Africa.  A recent study from Limpopo Province, 
SA, concluded that there is an increased relative risk of death in patients receiving PD 
compared to HD. (56)  
 
METHODS  
 
This retrospective cohort study was conducted at a single centre and compares survival 
outcomes of all patients receiving either HD or PD at Groote Schuur Hospital from 2010 
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to 2015. Ethical approval was granted by the University of Cape Town Human Research 
Ethics Committee.   
 
Information from routine 3-monthly clinic visits was confidentially captured and included 
clinical examination and baseline biochemical profiles as recommended by the Kidney 
Disease: Improving Global Outcomes (KDIGO) guidelines of best clinical practice. (67) Data 
was then combined with an existing database compiled by Dr Davidson et al. (68) 
 
Outcomes are shown as either death or censorship before death. Patients were censored at 
either transplantation, contract termination or if the patient was still alive at the end of the 
follow up period. Reasons for termination of the dialysis contract were if the patient moved 
to another hospital or if the patient was removed from the program due to compliance issues 
or terminal illness. Those patients receiving PD who were denied modality switch to HD were 
excluded from the final survival analysis. Patients failing PD requiring transfer to HD only 
receive modality switch if they remain suitable for transplantation. 
 
Kaplan Meier curves were calculated and illustrate the survival probability of the three 
subgroups being PD- assigned, HD- assigned and patients switching from PD to HD (PD→HD). 
Log- rank tests were performed to determine significant differences in the survival probability 
of the groups.   
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All statistical analysis was performed using Stata (Version 13.1; Stata Corp, College Station, 
Texas, USA).  Results were expressed as mean ± standard deviation (SD) and median ± 
interquartile range (IQR) for normal and skewed continuous variables respectively, and 
frequencies and percentages for categorical variables. Depending on the nature of the 
Table 1: Characteristics of patients according to original dialysis modality 
   HD 
n= 174 
PD 
n= 189 
Total 
n= 363 
p- value 
Median time on dialysis years, 
(IQR) 
2.3 (1.2-4.30) 1.9 (1.0-3.2) 2.1(1.1-3.7) 0.015 
   Mean age (years ±SD)    36.37±10.32 39.66±10.40 38.08±10.47 0.003 
Age distribution n (%)   
14- 24 years  25 (14.37) 18 (9.52) 43 (11.85) 0.100  
25- 34 years  51 (29.31) 41 (21.69) 92 (25.34)  
35- 44 years  50 (28.74) 63 (33.33) 113 (31.13)  
45- 60 years  48 (27.59) 67 (35.45) 115 (31.68)  
Gender n (%)      
Male  101 (58.05) 94 (49.74) 195 (53.72) 0.113  
Race n (%)      
African  98 (56.32) 60 (31.75) 158 (43.53) <0.001  
Mixed ethnicity/ Asian  73 (41.95) 122 (64.55) 195 (53.72)  
White  3 (1.72) 7 (3.70) 10 (2.75)  
Mean BMI (kg/m² ±SD)  24.51± 4.43 25.52± 4.43 25.06± 4.45 0.036 
BMI Classification n (%)      
Underweight  13 (8.33) 6 (3.26) 19 (5.59) 0.097 
Normal weight 77 (49.36) 85 (46.20) 162 (47.65)  
Overweight  49 (31.41) 62 (33.70) 111 (32.65)  
Obese  17 (10.90) 31 (16.85) 48 (14.12)  
Diabetes Mellitus n (%)  21 (12.07) 17 (9.29) 38 (10.64) 0.395  
HbA1C >8 (%)  6 (3.45) 9 (4.92) 15 (4.20) 0.219  
Hypertension n (%)  76 (47.20) 133 (73.08) 209 (60.93) <0.001 
Smoking (%)      
Never smoked  129 (81.13) 151 (82.07) 280 (81.63) 0.824  
Current or prior smoker  30 (18.87) 33 (17.93) 63 (18.37)  
HIV infected n (%)  15 (8.62) 6 (3.17) 21 (5.79) 0.026 
Chronic Hepatitis B n (%)  9 (5.17) 4 (2.12) 13 (3.58) 0.159 
CVD event n (%)  4 (2.44) 7 (3.83) 11 (3.17) 0.549 
Cause of ESRF n (%)      
Hypertension   66  (37.93) 60 (32.61) 126 (35.20) 0.139 
Chronic GN  41 (23.56) 65 (35.33) 106 (29.61)  
Diabetes Mellitus   21 (12.07) 14 (7.61) 35 (9.78)  
Other 46 (26.44) 45 (24.46) 91 (25.42)  
Previous transplant n (%)  28 (16.18) 20 (10.70) 48 (13.33) 0.126 
HD: haemodialysis, PD: peritoneal dialysis, IQR: interquartile range, BMI: body mass index, HIV: 
human immunodeficiency virus, CVD: cardiovascular disease, ESRF: end stage renal failure, GN: 
glomerulonephritis. Significant p- values are in bold. n varies due to missing data. All p-values 
calculated using the Fisher exact test.  
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variable, modality groups were compared using Anova, Kruskal-Wallis, Chi-squared and 
Fisher’s exact tests.  Using death as an endpoint, survival probabilities were estimated using 
Kaplan-Meier methods and compared using the log-rank test at 1, 2 and 5 years.  95% 
confidence intervals (CI) are indicated where appropriate. A p-value of 0.05 was considered 
statistically significant where appropriate. 
 
RESULTS 
 
363 patients were entered into the registry. Patients were not included if they had received 
less than 90 days of any form of dialysis, as they were not yet established on either modality. 
A total of 174 were assigned to HD and 189 were assigned to PD.  Table 1 illustrates the 
baseline data. Figure 1 illustrates how patients were analysed and indicates outcomes of each 
cohort.  
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The median follow up time for all patients was 2.74 years (SD± 2.27 years). Patients assigned 
to HD had the longest follow up period (3.13± 2.58 years).  The majority (68.31%) of patients 
were under the age of 45. Most patients assigned to HD where Black African (56.32%). A 
higher proportion of patients received PD only were non Black (68.25%).  
 
The most common cause for ESRF was hypertension (35.2%) followed by chronic 
glomerulonephritis (29.61%) and diabetic nephropathy (9.78%). Other causes 
(25.42%) included familial kidney diseases, lupus nephritis and other autoimmune disorders, 
tuberculosis, HIV associated nephropathy and post trauma related nephrectomy.  
 
 
Total on Day 91
n= 363
HD on Day 91
n=  174
Switched to PD
n= 6
Died within 5 
years
n= 1/ 6
Received 
Tranplant
n= 1/ 6
Remained on 
HD
n= 168
Died within 5 
years
n= 12/ 168
Received 
tranplant
n=  65/ 168
PD on Day 91
n= 189
Switched to HD
n=  42 
Died within 5 
years
n= 1/ 42
Received 
transplant
n= 18/ 42
Remained on 
PD
n= 147
Died within 5 
years
n= 26/ 147
Received 
tranplant
n= 48/ 147
 Figure 1: Consort flow diagram to show the allocation and outcomes of patients receiving 
haemodialysis and peritoneal dialysis.  
40 | P a g e  
 
The majority of deaths were related to infection (25%) and fluid overload (19%). (Figure 2.) 
The most common cause of death was fluid overload in the PD cohort and infection in the HD 
cohort. (Figure 3.) Fluid overload as a cause of death was defined as clinical fluid overload at 
the time of death with pulmonary oedema. 
 
 
 
25%
19%
14%
11%
11%
8%
6%
6%
Fluid overload
Infection- no relation to modality
Malignancy
Sudden death
Infection- related to modality
Unknown
CVA
Other
 Figure 2: Causes of death for all patients receiving dialysis. (n= 37) 
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Figure 3: Causes of death for patients as assigned to dialysis modality. (n= 37) 
 
0
2
4
6
8
10
Red= PD only
Blue= HD only
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Figure 4a: Kaplan-Meier survival curves for all PD and HD patients according to assigned 
modality.  Patients who switched from HD to PD (n=6) were removed from analysis. 
 
In the as-assigned analysis (Figure 4a.), patients assigned to HD showed a statistically 
superior survival probability with 98.68% (CI: 94.84- 99.67), 96.95 (CI: 91.98- 98.86) and 
83.52% (CI: 71.75- 90.70) survival at 1-, 2- and 5- years respectively while patients assigned 
to PD showed a survival probability 95.11% (95% CI:90.44- 97.53), 86.35% (95% CI: 79.26-
91.14) and 72.14% (95% CI: 58.46- 81.98) for the same intervals. (p=0.0093) 
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Figure 4b: Kaplan Meier curves for PD and HD patients as assigned to modality with those 
patients denied modality switch (n=11) and those switching from HD to PD (n=6) excluded. 
 
Having removed those PD patients whom modality switch was denied (Figure 4b.), the PD 
cohort showed an improved survival probability of 96.73% (95% CI: 92.32- 98.63), 89.95 
(95% CI: 83.17- 94.1) and 76.69 (95% CI: 60.97- 86.73) survival at 1-, 2- and 5- years 
respectively. (p= 0.145) 
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Figure 4c: Kaplan-Meier survival curves for patients switching from PD to HD against those 
who received PD and HD only. Those patients denied modality switch (n=11) and those 
switching from HD to PD (n=6) excluded. 
 
When those patients who switched from PD to HD were analysed (Figure 4c.), the survival 
probability at 1-, 2- and 5- years improved to 100%, 97.37% (95% CI: 82.75- 99.63) and 
97.37% (95% CI: 82.75- 99.63) for that group of patients. (p=0.001) 
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DISCUSSION 
 
This retrospective study analysed the mortality of patients on HD vs PD at Groote Schuur 
Hospital, Cape Town over a 5 year period (2010- 2015).   
 
The Western Cape guidelines for rationing chronic dialysis adopted by Groote Schuur Hospital 
highlight that patients accepted for RRT should be suitable for transplantation and that the 
ethical principal of utilitarianism should guide the allocation of dialysis in our resource limited 
setting. 
 
Potential RRT candidates are presented by the attending clinician to a committee of 
nephrologists with input from social workers, dieticians and nurses. A detailed psychosocial 
review is employed in the decision making process and factors such as insight, 
employment, schooling, living conditions, dependents and support are taken into account.  
Previous compliance issues and drug use are highlighted in the assessment. Access to running 
household water and number of household occupants is important for PD.   
 
An ethically endorsed prioritization policy exists with three categories. Category 1 patients 
must be given RRT as they have the potential to gain maximum benefit with the lowest chance 
of treatment failure. Therefore, resources will always be allocated to these patients. Category 
2 patients will be given RRT only if resources permit. Priority is given to those waiting the 
longest and those who have the best chance of good outcome. Both Category 1 and 2 patients 
must be suitable for transplantation. Category 3 patients are offered optimal medical 
treatment and are not offered RRT. (8)  
 
Transplanted patients who experience graft- failure and patients requiring modality switch 
are reconsidered for RRT in the same way as new patients.  An appeal procedure exists and 
an independent committee can assess the case if required. 
 
An audit performed at Groote Schuur from 2008- 2012 showed that only 46% of patients 
presented for RRT were accepted. Younger, employed individuals and those with a superior 
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psychosocial assessment are more likely to be accepted, however gender, marital status and 
area of residence were not seen to be predictors of acceptance. In univariate analysis, more 
black Africans were accepted than non-blacks, however, in multivariate analysis, race was not 
a predictor for acceptance. Diabetics and those with co-morbid diseases were less likely to be 
accepted. (9) 
 
The result of this process is that more patients under 50 years of age are accepted onto the 
program. The average age of this cohort is therefore younger than that reported 
by most other international studies. Black African patients are more likely to be initiated on 
HD as they tend to be living in overcrowded areas with limited access to amenities making PD 
more hazardous.  
 
Patients remain on PD until complications arise or transplantation occurs. Common reasons 
for switching modalities include Tenckhoff catheter malfunction, repeated peritonitis 
and inadequacy of dialysis. However, all patients at Groote Schuur Hospital requiring 
modality switch from PD to HD are reviewed for suitability for on-going treatment through an 
ethically endorsed process because of the limited slots for HD patients. We identified eleven 
patients who had originally been assigned to PD but were later refused modality switch either 
due to significant compliance issues or medical co-morbidities preventing transplantation, 
including malignancy and significant cardiovascular disease.  
 
There was a death rate of 10.6% recorded during the study period across all groups. This is 
significantly lower than other international studies and is likely due to the acceptance of 
younger patients without significant co-morbidities. (69–71)  
 
In the analysis of the as-assigned PD and HD cohorts, a statistically significant difference in 
survival probability was demonstrated in favour of HD. However, after removing the patients 
from the analysis who were denied modality switch, the difference in overall HD and PD 
survivals was no longer statistically significant. Patient survival over 5 years was significantly 
better in the group that switched from PD to HD when compared to the other two 
groups.  This may be due to the preservation of renal function and the delayed need for 
vascular access. This suggests that a PD first programme at our hospital is associated with 
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comparable outcomes between modalities and allows a greater number of patients to be 
treated due to limited HD slots. Early identification of patients failing PD and the appropriate 
timing of modality switch is highlighted by these data, especially given the high number of PD 
deaths due to fluid overload.  
 
However, in contrast, a recent SA study from Limpopo province conducted among 
predominantly rural-living patients showed that PD was an independent predictor of all-cause 
mortality (HR: 2.00, CI: 1.29- 3.10. p<002) when compared to HD. (56) This study reported 
poorer survival probabilities for PD and HD at 3 and 5 years than that seen in our study. The 
reason is likely due to limited resources and access to specialist health care. The average 
travelling distance for all patients in this cohort was more than 100km to the treatment 
centre. Cardiovascular disease and infection were seen as the most common causes of death, 
which is similar to the causes reported in our setting.  
 
Further study is required into the underlying risk factors for death in our cohort, including 
demographic, clinical and biochemical markers that may predict a poorer outcome in this 
setting. Fluid overload was the most common cause of death among patients receiving PD. 
This has lead the department to motivate for icodextrin in selected cases and increased use 
of automated PD. In addition, further analysis of patients denied modality switch is required 
to improve the selection of PD or HD. 
 
This study has been important in directing local treatment policies as well as providing 
information to similar dialysis centres in low and middle income countries.  This study is 
limited by its small sample size and it is recommended that a future prospective multicentre 
study be undertaken. The absence of analysis of risk factors for death in each group in this 
cohort is a limitation of the study. Cox-proportional hazard modelling in this instance along 
with competing risks analysis to measure survival on patients who were censored at the time 
of kidney transplantation is warranted. In addition we select younger patients with less co-
morbidities compared with those reported in other studies. This study identified the 
importance of early identification of patients failing PD particularly from fluid overload.  
Appropriate timing of modality switch may prevent premature death. 
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CONCLUSION 
 
There are numerous challenges to a successful PD first program in SA. A large proportion of 
the population faces a poor standard of living, insufficient access to electricity and running 
water and difficult access to healthcare facilities. In addition, the cost of PD fluid is also still 
restricting access for this lifesaving modality.   
  
Overall, the death rate in our cohort was lower than that reported in larger international 
studies. This is likely due to the known selection bias of our cohort with younger patients, free 
from other co-morbidities being selected. These selection criteria promote the best possible 
outcomes with our current limited resources.   
 
Large international studies have shown similar mortality outcomes for patients receiving 
either PD or HD. This paper indicates that PD is not statistically inferior to HD and those 
patients switching from PD to HD have the best survival outcomes. Therefore, the current PD 
first policy is justified in our setting, although interventions should be aimed at improving PD 
mortality outcomes with infection control and fluid balance management being shown as key 
areas.   
 
The complex decision of which modality to initiate a patient on needs to take into account 
the limited resources available in SA as well as the effect on quality of life with each modality. 
The appropriate switching of a patient’s dialysis modality should be seen as part of an 
integrated care plan, with timeous modality switch if required, which has been shown to 
improve survival in this setting.  
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